Comparative Pharmacology
Head-to-head clinical analysis: TAZVERIK versus VOYXACT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAZVERIK versus VOYXACT.
TAZVERIK vs VOYXACT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TAZVERIK is a histone methyltransferase EZH2 inhibitor. It selectively inhibits the enzymatic activity of EZH2, leading to decreased trimethylation of lysine 27 on histone H3 (H3K27me3), which results in reactivation of silenced genes and inhibition of proliferation in EZH2-mutant or wild-type cells.
GABAA receptor positive allosteric modulator; a neuroactive steroid that potentiates GABAergic inhibition.
600 mg orally twice daily, with or without food, for advanced epithelioid sarcoma. Continue until disease progression or unacceptable toxicity.
Adults: 200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 3.6 hours (range 1.6–7.1 hours) in patients with epithelioid sarcoma at steady state. Short half-life supports twice-daily dosing. Consider accumulation with renal or hepatic impairment.
Terminal elimination half-life approximately 37 hours (range 24-51 hours), supporting once-daily dosing with steady-state achieved in 5-8 days.
Primarily hepatobiliary excretion: approximately 70% of the dose recovered in feces as unchanged drug and metabolites, with <1% excreted renally as unchanged tazemetostat.
Primarily hepatic metabolism via CYP3A4, with 53% of the dose excreted in feces (mainly as metabolites) and 27% in urine (mostly as metabolites); less than 1% excreted unchanged in urine.
Category C
Category C
Antineoplastic, EZH2 Inhibitor
Antineoplastic